生物制剂在儿童炎症性肠病中的应用进展  

Application advance of biological agents in children with inflammatory bowel disease

作　　者：邹标 刘圣烜 舒赛男[1] Zou Biao;Liu Shengxuan;Shu Sainan(Department of Pediatrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院儿科,武汉430030

出　　处：《中华实用儿科临床杂志》2024年第11期869-873,共5页Chinese Journal of Applied Clinical Pediatrics

摘　　要：炎症性肠病(IBD)是一种病因不明的慢性、非特异性消化道炎症性疾病,其发病机制复杂,临床表现多样。生物疗法,特别是抗肿瘤坏死因子-α单抗从根本上改变了儿童IBD的治疗和病程。近年来,越来越多的生物制剂开始应用儿童IBD,现总结不同类型生物制剂在儿童IBD中的应用,阐述其作用机制、疗效、安全性、临床转换和联合应用等方面的最新研究进展,旨在提高儿科医师对IBD的优化治疗。Inflammatory bowel disease(IBD)is a chronic,nonspecific inflammatory disease of the digestive tract with unknown etiology,complicated pathogenesis and diverse clinical manifestations.Biologic therapies,particularly anti-tumor necrosis factor-αantibodies,have fundamentally changed the treatment and course of IBD in children.In recent years,more biologics have been applied to pediatric IBD.This review summarizes the application of different biologics in pediatric IBD and elaborates on the latest research progress in their mechanism of action,efficacy,safety,clinical conversion and combined application,so as to improve the optimal treatment of IBD by pediatricians.

关 键 词：炎症性肠病 生物疗法 儿童 

分 类 号：R725.7[医药卫生—儿科]